Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • APX3330
    • APX2009
    • Phentolamine Ophthalmic Solution 0.75%
    • Scientific Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia Completed
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Rexahn Pharmaceuticals Receives Notice from NYSE Alternext US LLC

Feb 27, 2009

Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial of SerdaxinTM to Treat Depression

Feb 2, 2009

Rexahn Completes Patient Enrollment in Phase IIa Clinical Trial of ZoraxelTM to Treat Erectile Dysfunction

Jan 26, 2009

Rexahn Pharmaceuticals Strengthens Clinical Development Leadership with Formation of Oncology Scientific Advisory Board

Nov 17, 2008

Rexahn Pharmaceuticals To Attend The Money Show November 6-8, 2008 in Washington DC

Nov 4, 2008

Rexahn Pharmaceuticals Receives FDA Approval to Initiate Phase II Trial for Serdaxin in Patients with Major Depressive Disorders

Sep 10, 2008

Rexahn Pharmaceuticals Names KCSA Strategic Communications as Investor Relations Counsel

Sep 8, 2008

Rexahn Pharmaceuticals Expands Cancer Patent Portfolio

Sep 3, 2008

Rexahn Pharmaceuticals Receives U.S. Patent for New Cancer Compounds

Jul 21, 2008

Rexahn Pharmaceuticals Added to Russell 3000 Index

Jun 30, 2008
    • 1...
    • 33
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use